Remibrutinib
Last Updated: 06/30/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 72 publications
A New Drug Target in Allergic Diseases: Bruton Tyrosine Kinase.
Journal: Journal of investigational allergology & clinical immunology
Published: April 27, 2026
Remibrutinib: Insights Into Its Mechanism of Action and Use for Dermatologic Conditions.
Journal: Journal of drugs in dermatology : JDD
Published: April 03, 2026
Remibrutinib (Rhapsido) for chronic spontaneous urticaria.
Journal: Trends in pharmacological sciences
Published: April 03, 2026
Bruton protein-tyrosine kinase (BTK) FDA-approved small molecule inhibitors used for the management of neoplastic and inflammatory disorders.
Journal: Pharmacological research
Published: March 31, 2026
Remibrutinib impact on disease control, sleep, and quality of life: Analysis of phase 3 REMIX-1/2.
Journal: Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology
Published: March 13, 2026
Solar urticaria successfully treated with Remibrutinib.
Journal: The journal of allergy and clinical immunology. In practice
Published: March 11, 2026
Safety of remibrutinib in chronic spontaneous urticaria: a pooled analysis of REMIX-1 and REMIX-2 trials.
Journal: The journal of allergy and clinical immunology. In practice
Published: March 02, 2026
Bruton's Tyrosine Kinase Inhibitors in Multiple Sclerosis: Mechanistic Considerations Across Relapsing and Progressive Disease.
Journal: Molecules (Basel, Switzerland)
Published: March 02, 2026
Efficacy and safety of pharmacological treatment for Sjögren's disease: a network meta-analysis.
Journal: Zeitschrift fur Rheumatologie
Published: February 26, 2026
Indirect Comparison of Remibrutinib and Dupilumab in Omalizumab-Refractory Chronic Spontaneous Urticaria.
Journal: Journal of the American Academy of Dermatology
Published: February 16, 2026
Involvement of Btk in Cardiovascular Disease and Its Therapeutic Targeting.
Journal: Circulation
Published: February 09, 2026
Investigations of remibrutinib in models pertinent to multiple sclerosis.
Journal: Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics
Published: January 22, 2026
Last Updated: 06/30/2026